FDA Sings Paeans To Postmarket Vigilance: “Lower Cost,” Quicker Approvals
This article was originally published in The Gray Sheet
Executive Summary
FDA's plan to hire a new chief economist is consistent with Commissioner Mark McClellan's pledge to evaluate the agency's cost efficiency as a top priority of his tenure